NewAmsterdam Pharma Company (NAMS) Price & Analysis

Compare

204 Followers

NAMS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$14.06 - $27.29

Previous CloseN/A

Volume118.30K

Average Volume (3M)788.41K

Market Cap

$2.44B

Enterprise Value$1.57B

Total Cash (Recent Filing)$808.48M

Total Debt (Recent Filing)$389.00K

Price to Earnings (P/E)―

Beta1.92

Next Earnings

Nov 17, 2025

EPS Estimate

-0.39

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding112,270,676

10 Day Avg. Volume697,927

30 Day Avg. Volume788,408

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.64

Enterprise Value/Revenue33.28

Enterprise Value/Gross Profit33.28

Enterprise Value/Ebitda-6.13

Forecast

1Y Price Target

$41.29

Price Target Upside79.83% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Alzheimer's Disease ResearchObi leads to statistically significant and clinically meaningful reductions in p-tau217, a biomarker associated with Alzheimer's disease.

Lipid-Lowering Therapy MarketObicetrapib is believed to offer a differentiated product profile in the marketplace.

Trial ResultsNewAmsterdam announced positive top-line Alzheimer’s disease biomarker data from the prespecified sub-study of the Phase III BROADWAY trial.

Bears Say

Clinical Trial ResultsIt is important to recognize this is only a single-arm trial and therefore would require additional exploration to demonstrate contribution of the components.

Investor ConcernsThe lack of numerical data in Merck’s press release could lead some investors to assume the results are not as strong as the previous Phase II trials.

NewAmsterdam Pharma Company News

NewAmsterdam Pharma reports Q2 revenue $19.145M vs $2.279M last year

“Fueled by strong momentum in the first half of 2025, obicetrapib is rapidly advancing towards patients worldwide, potentially...

2d ago

NAMS

NewAmsterdam Pharma presents data from BROADWAY trial at AAIC

NewAmsterdam Pharma (NAMS) announced full data from the prespecified Alzheimer’s disease biomarker analysis in the BROADWAY clinical trial....

9d ago

NAMS

NewAmsterdam Pharma initiated with a Neutral at Goldman Sachs

Goldman Sachs initiated coverage of NewAmsterdam Pharma (NAMS) with a Neutral rating and $27 price target The firm...

22d ago

NAMS

Promising Future for NewAmsterdam Pharma: Buy Rating Backed by Strong Financials and Positive Trial Data

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on NAMS stock, giving a Buy rating yesterday....

5h ago

NAMS

NewAmsterdam Pharma Reports Q2 2025 Financial Results

Newamsterdam Pharma Company N.V. ( ($NAMS) ) has released its Q2 earnings. Here is a breakdown of the...

1d ago

NAMS

Promising Developments and Strong Financial Position Support Buy Rating for NewAmsterdam Pharma

In a report released today, Serge Belanger from Needham maintained a Buy rating on NewAmsterdam Pharma Company, with...

2d ago

NAMS

Buy Rating for NewAmsterdam Pharma Driven by Promising Trial Developments and Strategic Advancements

William Blair analyst Matt Phipps has maintained their bullish stance on NAMS stock, giving a Buy rating today....

2d ago

NAMS

Optimistic Buy Rating for NewAmsterdam Pharma Driven by Promising Cardiometabolic Drug Developments

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on NAMS stock, giving a Buy rating...

2d ago

NAMS

Buy Rating for NewAmsterdam Pharma: Promising Developments in Alzheimer’s and Cardiovascular Trials

Leerink Partners analyst Roanna Ruiz maintained a Buy rating on NewAmsterdam Pharma Company on July 30 and set...

7d ago

NAMS

Promising Alzheimer’s Biomarker Data and Expert Enthusiasm Drive Buy Rating for NewAmsterdam Pharma

NewAmsterdam Pharma Company, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger...

8d ago

NAMS

NewAmsterdam Pharma’s Promising Phase 3 Alzheimer’s Trial Results

An update from NewAmsterdam Pharma Company ( ($NAMS) ) is now available. On July 30, 2025, NewAmsterdam Pharma...

9d ago

NAMS

NewAmsterdam Pharma Updates Employment Agreement with Executive

The latest update is out from NewAmsterdam Pharma Company ( ($NAMS) ). On July 11, 2025, NewAmsterdam Pharma...

28d ago

NAMS

NewAmsterdam Pharma participates in a conference call with Cantor Fitzgerald

Conference call with management will be held on June 30 at 3 pm hosted by Cantor Fitzgerald. Webcast...

1M ago

NAMS

NewAmsterdam Pharma initiated with a Buy at Citi

Citi initiated coverage of NewAmsterdam Pharma (NAMS) with a Buy rating and $42 price target The LDL cholesterol...

2M ago

NAMS

NAMS FAQ

What was NewAmsterdam Pharma Company’s price range in the past 12 months?

NewAmsterdam Pharma Company lowest stock price was $14.06 and its highest was $27.29 in the past 12 months.

What is NewAmsterdam Pharma Company’s market cap?

NewAmsterdam Pharma Company’s market cap is $2.44B.

When is NewAmsterdam Pharma Company’s upcoming earnings report date?

NewAmsterdam Pharma Company’s upcoming earnings report date is Nov 17, 2025 which is in 101 days.

How were NewAmsterdam Pharma Company’s earnings last quarter?

NewAmsterdam Pharma Company released its earnings results on Aug 06, 2025. The company reported -$0.148 earnings per share for the quarter, beating the consensus estimate of -$0.23 by $0.082.

Is NewAmsterdam Pharma Company overvalued?

According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does NewAmsterdam Pharma Company pay dividends?

NewAmsterdam Pharma Company does not currently pay dividends.

What is NewAmsterdam Pharma Company’s EPS estimate?

NewAmsterdam Pharma Company’s EPS estimate is -0.39.

How many shares outstanding does NewAmsterdam Pharma Company have?

NewAmsterdam Pharma Company has 112,270,676 shares outstanding.

What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?

NewAmsterdam Pharma Company reported an EPS of -$0.148 in its last earnings report, beating expectations of -$0.23. Following the earnings report the stock price went up 8.698%.

Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?

Currently, no hedge funds are holding shares in NAMS

NewAmsterdam Pharma Company Stock Smart Score

Outperform

Fundamentals

Return on Equity

-28.43%

Trailing 12-Months

Asset Growth

67.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

NewAmsterdam Pharma Company

NewAmsterdam Pharma Company (NAMS) is a clinical-stage biopharmaceutical company focused on the research and development of transformative therapies to address cardiovascular diseases. The company operates within the biopharmaceutical sector, leveraging advanced scientific research to create novel treatments. Its core products include investigational therapies aimed at managing and preventing cardiovascular conditions, with a primary focus on dyslipidemia and other metabolic disorders.

NewAmsterdam Pharma Company (NAMS) Earnings & Revenues

Historic Earnings Reports

NAMS Stock 12 Month Forecast

Average Price Target

$41.29

▲(79.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","34":"$34","53":"$53","24.5":"$24.5","43.5":"$43.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,24.5,34,43.5,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.28,23.643076923076926,26.006153846153847,28.369230769230768,30.732307692307693,33.09538461538462,35.458461538461535,37.82153846153846,40.184615384615384,42.54769230769231,44.91076923076923,47.27384615384615,49.636923076923075,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.28,22.81923076923077,24.35846153846154,25.89769230769231,27.43692307692308,28.97615384615385,30.515384615384615,32.05461538461539,33.59384615384616,35.13307692307693,36.6723076923077,38.21153846153847,39.75076923076923,{"y":41.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.28,21.45846153846154,21.63692307692308,21.815384615384616,21.993846153846157,22.172307692307694,22.35076923076923,22.52923076923077,22.70769230769231,22.886153846153846,23.064615384615387,23.243076923076924,23.421538461538464,{"y":23.6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.26,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.42,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.29,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.29,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >